Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Azeliragon - vTv Therapeutics

Drug Profile

Azeliragon - vTv Therapeutics

Alternative Names: PF-04494700; PF-4494700; TTP-488

Latest Information Update: 02 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TransTech Pharma
  • Developer Pfizer; TransTech Pharma; vTv Therapeutics LLC
  • Class Antidementias; Diethylamines; Imidazoles; Small molecules
  • Mechanism of Action Advanced glycosylation end product receptor antagonists; Amyloid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease
  • Discontinued Diabetic nephropathies

Most Recent Events

  • 27 Jun 2019 Phase-II/III clinical trials in Alzheimer's disease (In adults, In the elderly) in USA (PO) (NCT03980730)
  • 27 Feb 2019 vTv Therapeutics plans a phase II/III trial for Alzheimer’s Disease in June 2019 (PO, Capsule) (NCT03980730)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top